Research progress of CAR-T in the treatment of hepatocellular carcinoma

VernacularTitle:嵌合抗原受体T细胞在肝细胞癌治疗中的研究进展
Author: Bing FU ¹ ; Yi BAI ; Hao WU ; Yamin ZHANG
Author Information

1. 天津医科大学一中心临床学院，天津　300192
Keywords: Carcinoma, hepatocellular; Neoplasms; Immunotherapy; Chimeric antigen receptor-modified T-cell
From: Chinese Journal of Hepatobiliary Surgery 2022;28(2):146-150
CountryChina
Language:Chinese
Abstract: In recent years, chimeric antigen receptor-modified T-cell (CAR-T) immunotherapy, as a new idea of tumor immunotherapy, has been proved to be effective in hematological diseases. More and more studies have been focusing on this field. At present, some progress have been made in the treatment of hepatocellular carcinoma with CAR-T, but some problems such as solid tumor inherent barrier, tumor microenvironment, immune escape and specific tumor associated antigens still need to be further figure out. Nevertheless, CAR-T immunotherapy will provide a more cutting-edge treatment for hepatocellular carcinoma immunotherapy. In addition, the combination of CAR-T and other methods may also be the direction to be explored in the next step.